Objective: To describe the clinical efficacy of tixagevimab/cilgavimab in pre-exposure prophylaxis in patients at risk of severe coronavirus disease 2019 (COVID-19) and unresponsive to vaccination (anti-severe acute respiratory syndrome coronavirus 2 antibodies <260 binding antibody units/ml) in rheumatology.
Methods: In this multicentre observational study we included patients with autoimmune or inflammatory diseases who received pre-exposure prophylaxis with tixagevimab/cilgavimab between December 2021 and August 2022. The endpoint was incidence of COVID-19 and its severity.
Results: Tixagevimab/cilgavimab was administered to 115 patients with a median age of 62 years [interquartile range (IQR) 52-71], chronic arthritis (n = 53), connective tissue disease (n = 38) or vasculitis (n = 11). The main background immunosuppressants were rituximab (n = 98), corticosteroids [n = 62; median dose 5 mg (95% CI 5-8)] and methotrexate (n = 48). During a median follow-up of 128 days (IQR 93-173), COVID-19 occurred in 23/115 patients (20%) and the omicron variant was identified for the eight genotyped patients. During the study period, the average weekly incidence was 1071/100 000 inhabitants in Île-de-France vs 588/100 000 in our patients. Patients who received a two-injection regimen had a lower risk of infection than those with a single injection [16/49 (33%) vs 5/64 (8%), P = 0.0012]. The COVID-19-positive patients did not differ from uninfected patients concerning age, comorbidities, underlying rheumatic disease and immunosuppressants. All COVID-19 cases were non-severe. The tolerance of injections was excellent.
Conclusion: In a population with autoimmune or inflammatory diseases at risk of severe COVID-19 unresponsive to vaccination, pre-exposure prophylaxis withy tixagevimab/cilgavimab was associated with a lower incidence of COVID-19 and no severe infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/kead449 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study.
Infect Dis Ther
December 2024
Infectious Diseases Institute, Soroka University Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Introduction: Despite the declining public health emergency status, COVID-19 still poses significant risks, especially for immunocompromised individuals. We aimed to evaluate the effectiveness of tixagevimab-cilgavimab (T-C) prophylaxis in preventing severe COVID-19 in patients with hematologic malignancies (HM) treated with anti-CD20 therapy during the early Omicron variant phase of the pandemic.
Methods: The European Society of Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses (ESGREV) conducted a multicenter retrospective cohort study involving 15 centers from 5 countries.
Real-world experience of tixagevimab/cilgavimab prophylaxis in Japanese patients with immunodeficiency.
J Infect Chemother
December 2024
Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, 113-8519, Tokyo, Japan. Electronic address:
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe illness and mortality in patients with immunodeficiency. Although vaccination has been recommended, the induction of protective antibodies by immunization, and thus the disease-preventive effect, has proven insufficient in immunodeficient patients, especially in those with predominantly antibody deficiency. A monoclonal antibody combination of tixagevimab and cilgavimab (TIX/CIL) was developed as a pre-exposure prophylaxis (PrEP).
View Article and Find Full Text PDFImmunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study.
Hum Vaccin Immunother
December 2024
Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Article Synopsis
- A study was conducted to assess the effectiveness of Tixagevimab-Cilgavimab in immunocompromised children and adolescents weighing between 20 to >40 kg, with two different dosage groups based on weight (300 mg for 20 to <40 kg and 600 mg for ≥40 kg).
- After measuring antibody levels at multiple time points, results showed that both dosages produced high levels of neutralizing antibodies against the ancestral SARS-CoV-2 strain, significantly surpassing levels in healthy children who had received three BNT162b2 vaccinations.
- Adverse effects were mild and slightly more common in the heavier dosage group; overall, the study concluded that the lower dosage was just as effective as the higher
Pre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center Experience.
New Microbiol
November 2024
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy.
Article Synopsis
- Pre-exposure prophylaxis with Tixagevimab/Cilgavimab has effectively reduced COVID-19 risks in immunocompromised patients, but its efficacy is limited against the Kraken variant (XBB.1.5).
- A study involving kidney transplant patients on this treatment showed only one asymptomatic infection during a six-month follow-up, with no hospitalizations or COVID-related deaths.
- The results suggest Tixagevimab/Cilgavimab may still be a beneficial preventive option for immunocompromised individuals, underlining the need for further clinical research on this topic.
Tixagevimab-cilgavimab for preventing breakthrough COVID-19 in dialysis patients: a prospective study.
Clin Kidney J
November 2024
Division of Nephrology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: The effectiveness of tixagevimab-cilgavimab as pre-exposure prophylaxis (PrEP) against breakthrough coronavirus disease 2019 (COVID-19) in dialysis patients remains uncertain due to limited data.
Methods: In this multicenter prospective study, we enrolled vaccinated dialysis patients and divided them into two groups: a tixagevimab-cilgavimab group (received a 150 mg/150 mg intramuscular dose of tixagevimab-cilgavimab) and a control group (age-matched patients not receiving tixagevimab-cilgavimab). The primary outcome was the breakthrough COVID-19 rate at 6 months, whereas secondary outcomes included COVID-19-related hospitalization, intensive care unit admission, endotracheal intubation and mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!